Raymond James Cuts Price Target On AngioDynamics
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate.
At 2.2x EV/sales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued execution, supporting the Strong Buy rating.
The revenue momentum is real and will carry into F23 (guide of 8-10% growth), the analyst wrote. He views back-order fulfillment as a source of cushion in the guidance. The stock price reaction is a bit disappointing given the guidance.
Related: AngioDynamics' Q4 Top-Line Beats Street View, Issues Mixed FY23 Guidance.
The analyst notes that hospital staff shortages are still an issue but likely did not curb revenue growth. Monthly volumes were similar throughout the quarter.
ANGO feels comfortable with the demand profile, even in a recessionary environment.
ANGO reduced the back-order to $8 million (from $11 million). This backlog may have some double-counting, but it's not significant (~10%). The company's anti-competitive lawsuit against Bard has been pushed to mid-September from early July, with low expectations.
Price Action: ANGO shares are up 5.74% at $21.17 during the market session on the last check Wednesday.
Latest Ratings for ANGO
Date | Firm | Action | From | To |
|---|---|---|---|---|
Oct 2021 | Canaccord Genuity | Upgrades | Hold | Buy |
Aug 2021 | Oppenheimer | Initiates Coverage On | Perform | |
Jul 2021 | Canaccord Genuity | Maintains | Hold |
View More Analyst Ratings for ANGO
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
